BioCardia to Participate in a Fireside Chat at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
Rhea-AI Summary
BioCardia (Nasdaq: BCDA) will participate virtually in a fireside chat at the A.G.P. Healthcare Company Showcase.
Timing: 11:40 AM ET on Wednesday, May 20, 2026. According to BioCardia, investors can register for the conference and view the session online.
Positive
- None.
Negative
- None.
News Market Reaction – BCDA
In the May 19 session, BCDA gained 5.64%, reflecting a notable positive market reaction. Argus tracked a peak move of +22.2% during that session. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 15 | Q1 2026 earnings | Positive | -7.3% | Reported narrower net loss and supportive regulatory feedback for core programs. |
| May 11 | Earnings call notice | Neutral | +0.9% | Announced timing and access details for Q1 2026 results call. |
| May 08 | FDA alignment Helix | Positive | +1.8% | FDA agreed on Helix catheter clearance pathways with no major safety concerns. |
| Apr 28 | Japanese patent | Positive | -1.7% | Announced allowance of Japanese patent for Heart3D Fusion Imaging software. |
| Apr 20 | PMDA consultation | Positive | +5.9% | PMDA found CardiAMP data likely sufficient to support Japan market clearance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive regulatory and IP updates often saw mixed price reactions, with some favorable announcements followed by declines, indicating inconsistent trading responses to news.
Over the past month, BioCardia reported multiple regulatory and strategic milestones. On April 20, Japan’s PMDA indicated CardiAMP data is likely sufficient for market clearance, which was followed by U.S. FDA alignment on Helix catheter pathways on May 8. A Japanese patent allowance for Heart3D was disclosed on April 28. Q1 2026 results on May 15 showed a narrower net loss but were met with a share price decline, framing today’s conference appearance against a backdrop of regulatory progress and financial strain.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SUNNYVALE, Calif., May 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, will participate virtually in a fireside chat at A.G.P.'s Healthcare Company Showcase.
Fireside Chat Details:
- Time: 11:40 AM ET
- Date: Wednesday, May 20, 2026
Investors can register for the conference and view the fireside chat here.
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms for the treatment of heart disease. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit: www.BioCardia.com.
Media Contact: Miranda Peto, Investor Relations Email: mpeto@BioCardia.com Phone: 650-226-0120 Investor Contact: David McClung, Chief Financial Officer Email: investors@BioCardia.com Phone: 650-226-0120